SG10202004858TA - Composition and method for aiding sleep - Google Patents

Composition and method for aiding sleep

Info

Publication number
SG10202004858TA
SG10202004858TA SG10202004858TA SG10202004858TA SG10202004858TA SG 10202004858T A SG10202004858T A SG 10202004858TA SG 10202004858T A SG10202004858T A SG 10202004858TA SG 10202004858T A SG10202004858T A SG 10202004858TA SG 10202004858T A SG10202004858T A SG 10202004858TA
Authority
SG
Singapore
Prior art keywords
composition
aiding sleep
aiding
sleep
Prior art date
Application number
SG10202004858TA
Inventor
Lan Bo Chen
Original Assignee
Lan Bo Chen
Sequential Medicine Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lan Bo Chen, Sequential Medicine Ltd filed Critical Lan Bo Chen
Publication of SG10202004858TA publication Critical patent/SG10202004858TA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • A61K9/4825Proteins, e.g. gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891Coated capsules; Multilayered drug free capsule shells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
SG10202004858TA 2014-02-06 2015-02-04 Composition and method for aiding sleep SG10202004858TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461936566P 2014-02-06 2014-02-06

Publications (1)

Publication Number Publication Date
SG10202004858TA true SG10202004858TA (en) 2020-06-29

Family

ID=53753899

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10202004858TA SG10202004858TA (en) 2014-02-06 2015-02-04 Composition and method for aiding sleep

Country Status (22)

Country Link
US (2) US9427409B2 (en)
EP (2) EP3102189B1 (en)
JP (1) JP6338683B2 (en)
KR (1) KR101774721B1 (en)
CN (2) CN105899194B (en)
AU (1) AU2015214285B2 (en)
BR (1) BR112016017742A2 (en)
CA (1) CA2934595C (en)
DK (1) DK3102189T3 (en)
ES (1) ES2759452T3 (en)
HK (1) HK1222580A1 (en)
HR (1) HRP20192119T8 (en)
HU (1) HUE047654T2 (en)
MX (2) MX2016010051A (en)
MY (1) MY177906A (en)
NZ (1) NZ720813A (en)
PL (1) PL3102189T3 (en)
PT (1) PT3102189T (en)
RS (1) RS59800B1 (en)
SG (1) SG10202004858TA (en)
TW (1) TWI730939B (en)
WO (1) WO2015120006A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011232408B2 (en) 2010-03-24 2015-07-30 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
SG10202004858TA (en) * 2014-02-06 2020-06-29 Lan Bo Chen Composition and method for aiding sleep
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
JP2019514977A (en) * 2016-05-06 2019-06-06 フィジシャンズ シール,エルエルシー Valerian compositions and related methods
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (en) 2016-07-22 2017-11-30 Flamel Ireland Ltd FORMULATIONS OF GAMMA-MODIFIED RELEASE HYDROXIBUTIRATE WITH IMPROVED PHARMACOCINETICS
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
JP2022509759A (en) * 2018-11-06 2022-01-24 シークエンシャル・メディシン・リミテッド Compositions and methods for sleep assistance
KR20210094513A (en) 2018-11-19 2021-07-29 재즈 파마슈티칼즈 아일랜드 리미티드 Alcohol-Resistant Drug Formulations
EP3930702A1 (en) 2019-03-01 2022-01-05 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
CN110075302A (en) * 2019-04-19 2019-08-02 陶燃 It is a kind of to treat depression and the composition of insomnia and application thereof
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE229807T1 (en) * 1996-10-11 2003-01-15 Medichemie Ag CHRONIC USE OF LORAZEPAM AND DIPHENHYDRAMINE
EP1005863A1 (en) * 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
CA2366791A1 (en) * 1999-04-06 2000-10-12 Kamal K. Midha Pharmaceutical dosage form for pulsatile delivery of d-threo-methylphenidate and a second cns stimulant
EP1064937A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
US6485746B1 (en) * 2000-08-25 2002-11-26 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
PT1206248E (en) * 1999-08-26 2003-11-28 Neurocrine Biosciences Inc SEDATIVE-HYPNOTIC COMPOSITIONS OF CONTROLLED LIBERATION AND METHODS RELATED TO THE SAME
KR100540035B1 (en) * 2002-02-01 2005-12-29 주식회사 태평양 Multi-stage oral drug controlled-release system
US20050038042A1 (en) * 2002-11-15 2005-02-17 Jenet Codd Modified release composition comprising a short-acting hypnotic for treatment of sleep disorders
US20050031688A1 (en) * 2003-08-04 2005-02-10 Ayala William J. Positive wakeup pharmaceutical sleep system with compatible pre-bedtime administration
AU2004287485A1 (en) * 2003-11-05 2005-05-19 Santarus, Inc. Combination of proton pump inhibitor and sleep aid
US20060084659A1 (en) * 2004-10-19 2006-04-20 Michael Davis Augmentation of psychotherapy with cannabinoid reuptake inhibitors
GB0423964D0 (en) * 2004-10-28 2004-12-01 Jagotec Ag Dosage form
CA2590802A1 (en) * 2004-12-20 2006-06-29 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
WO2006133349A2 (en) * 2005-06-08 2006-12-14 Alpharma, Inc. Orally disintegrable sleep aid formulations
US20070020333A1 (en) * 2005-07-20 2007-01-25 Chin-Chih Chiang Controlled release of hypnotic agents
FR2889811B1 (en) * 2005-08-19 2009-10-09 Sanofi Aventis Sa ASSOCIATION OF A HYPNOTIC AGENT HAS LONG LASTING ACTION AND A SHORT-ACTING HYPNOTIC AGENT, A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AND ITS THERAPEUTIC USE.
US20070190130A1 (en) * 2006-02-16 2007-08-16 Mark William A Protein hydrolysate excipients
WO2008075372A1 (en) * 2006-12-18 2008-06-26 Lupin Limited Controlled release dosage forms of zolpidem
US20080248106A1 (en) * 2007-04-05 2008-10-09 Marvin Heuer Melatonin-based composition for improved sleep
US20080254121A1 (en) 2007-04-10 2008-10-16 Iomedix Sleep International Srl Multi-layer melatonin composition
US20080311162A1 (en) * 2007-05-16 2008-12-18 Olivia Darmuzey Solid form
CA2767576C (en) * 2009-07-08 2020-03-10 Charleston Laboratories Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
GB201003731D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
IT1401142B1 (en) * 2010-07-26 2013-07-12 Ambros Pharma S R L PROCEDURE FOR THE PREPARATION OF CONTROLLED TABLETS INCLUDING MELATONIN
US20130078304A1 (en) * 2011-09-28 2013-03-28 Taiwan Biotech Co., Ltd. Controlled release formulation for treating sleep disorders
CN103550775B (en) * 2013-10-18 2017-08-25 广州共禾医药科技有限公司 A kind of anti-insomnia composition and its application and the multiphase pulse prepared using said composition understand suddenly preparation and preparation method thereof
SG10202004858TA (en) * 2014-02-06 2020-06-29 Lan Bo Chen Composition and method for aiding sleep

Also Published As

Publication number Publication date
BR112016017742A2 (en) 2018-06-26
CN110604727A (en) 2019-12-24
EP3102189B1 (en) 2019-09-04
EP3632416A1 (en) 2020-04-08
CN105899194A (en) 2016-08-24
DK3102189T3 (en) 2019-12-02
RS59800B1 (en) 2020-02-28
AU2015214285B2 (en) 2020-07-23
HRP20192119T8 (en) 2020-08-21
US20150216811A1 (en) 2015-08-06
HK1222580A1 (en) 2017-07-07
KR20160057479A (en) 2016-05-23
KR101774721B1 (en) 2017-09-04
PL3102189T3 (en) 2020-05-18
EP3102189A1 (en) 2016-12-14
MY177906A (en) 2020-09-25
MX2020003139A (en) 2020-07-28
HRP20192119T1 (en) 2020-03-06
AU2015214285A1 (en) 2016-06-23
JP6338683B2 (en) 2018-06-06
ES2759452T3 (en) 2020-05-11
WO2015120006A1 (en) 2015-08-13
NZ720813A (en) 2021-12-24
US20160346216A1 (en) 2016-12-01
PT3102189T (en) 2019-12-11
EP3102189A4 (en) 2017-07-12
TWI730939B (en) 2021-06-21
CA2934595A1 (en) 2015-08-13
CA2934595C (en) 2022-06-21
US9427409B2 (en) 2016-08-30
HUE047654T2 (en) 2020-05-28
CN105899194B (en) 2019-10-25
MX2016010051A (en) 2017-05-04
TW201538160A (en) 2015-10-16
JP2016536371A (en) 2016-11-24

Similar Documents

Publication Publication Date Title
HRP20192119T8 (en) Composition and method for aiding sleep
HK1243640A1 (en) Methods and compositions for treating ulcers
FI3215147T3 (en) Neuro-attenuating norketamine compounds and methods
GB2524060B (en) Controller and method
GB201407711D0 (en) Communnication system and related method
IL246879B (en) Apilimod compositions and methods for using same
GB201501258D0 (en) Controller and method
SG11201608128UA (en) Polishing composition and polishing method
HK1243342A1 (en) Compounds and methods
GB201414369D0 (en) Kit and method
GB201705822D0 (en) Proppant composition and method
SE1451374A1 (en) Arrangement and method for force compensation in electricalmachines
HK1223837A1 (en) Compositions and methods for reducing overdose
IL246870B (en) Method for preparing 1-alkyl-3-difluoromethyl-5-fluoro-1h-pyrazole-4-carbaldehydes and 1-alkyl-3-difluoromethyl-5-fluoro-1h-pyrazole-4-carboxylates
IL246831B (en) Method for producing 1-indanoles and 1-indanamines
EP3009173A4 (en) Assisted-training system and method for billiards
GB201415250D0 (en) Compound and method
HK1220676A1 (en) Arrangement and method
EP3185901C0 (en) Compound and method
GB201421385D0 (en) Composition and method for treating nematodes
GB201416082D0 (en) Method and uses
EP3109243A4 (en) Gamma-butylolactone composition and production method therefor
GB201421947D0 (en) Elecroplating method and composition
PL3134581T3 (en) Method and soil-stabilizing means
GB201420773D0 (en) Compound and method